Operational Experience of the Rospotrebnadzor Specialists during the Epidemic of Mpox in Eastern and Central Africa in 2024

The paper presents the results of work of the Russian and African experts on the study of the epidemiological and clinical features of mpox in some countries of Eastern (Republic of Rwanda, Uganda, Burundi) and Central (Republic of the Congo) Africa in the fall of 2024. An analysis of the epidemiological data obtained in the countries under consideration showed that in most cases, mpox was reported in patients of the pediatric age group. The disease was equally registered in both men and women. The clinical course of the disease was represented by mild and moderate severe forms. Severe cases of the disease have been reported only among patients with immunosuppression, untreated HIV infection or other somatic and/or infectious pathologies, as well as in children under 2 years of age. Pregnant patients also had a mild form of mpox. No deaths were reported. Monkey pox was accompanied with a simultaneous increase in cases of Varicella Zoster virus disease in the Republics of Burundi and Uganda. This circumstance often led to the registration of patients with that infection as suspected but unconfirmed cases of mpox. People with herpetic manifestations also fell into this category. Rospotrebnadzor specialists provided consulting and practical assistance to the African colleagues. Russian-made reagent kits for detecting DNA of the monkeypox virus using PCR were transferred to each country. Based on the results of the joint work, a number of relevant areas for studying the circulation of the causative agent of this infectious disease, the clinical and epidemiological features of it in the countries of East and Central Africa have been identified.

1. WHO. Mpox outbreak. (Cited 28 Feb 2025). [Internet]. Available from: https://www.who.int/emergencies/situations/mpoxoutbreak/.

2. Current ICTV Taxonomy Release. (Cited 28 Feb 2025). [Internet]. Available from: https://ictv.global/taxonomy/.

3. Onishchenko G.G., Kirillov I.A., Makhlai A.A., Borisevich S.V. [Ortopoxviruses: past, present and future]. Vestnik RAMN [Annals of the Russian Academy of Medical Sciences]. 2020; 75(4):300–5. DOI: 10.15690/vramn1363.

4. Supotnitsky M.V. [Monkeypox: a poorly-studied biological threat to Russia]. [Journal of NBC Protection Corps]. 2022; 6(2):152–77. DOI: 10.35825/2587-5728-2022-6-2-152-177.

5. Branda F., Ceccarelli G., Ciccozzi M., Scarpa F. First cases of mpox Clade I outside of Africa: genetic insights on its evolution. Infect. Dis. 2024; 56(11):1003–5. DOI: 10.1080/23744235.2024.2399776.

6. Masirika L.M., Udahemuka J.C., Schuele L., Ndishimye P., Otani S., Mbiribindi J.B., Marekani J.M., Mambo L.M., Bubala N.M., Boter M., Nieuwenhuijse D.F., Lang T., Kalalizi E.B., Musabyimana J.P., Aarestrup F.M., Koopmans M., Oude Munnink B.B., Siangoli F.B. Ongoing mpox outbreak in Kamituga, South Kivu province, associated with monkeypox virus of a novel Clade I sub-lineage, Democratic Republic of the Congo, 2024. Euro Surveill. 2024; 29(11):2400106. DOI: 10.2807/1560-7917.ES.2024.29.11.2400106.

7. Kuppalli K., Dunning J., Damon I., Mukadi-Bamuleka D., Mbala P., Ogoina D. The worsening mpox outbreak in Africa: a call to action. Lancet Infect. Dis. 2024; 24(11):1190–2. DOI: 10.1016/S1473-3099(24)00577-2.

8. Beeson A., Styczynski A., Hutson C.L., Whitehill F., Angelo K.M., Minhaj F.S., Morgan C., Ciampaglio K., Reynolds M.G., McCollum A.M., Guagliardo S.A.J. Mpox respiratory transmission: the state of the evidence. Lancet Microbe. 2023; 4(4):e277-e283. DOI: 10.1016/S2666-5247(23)00034-4.

9. Sanchez Clemente N., Coles C., Paixao E.S., Brickley E.B., Whittaker E., Alfven T., Rulisa S., Agudelo Higuita N., Torpiano P., Agravat P., Thorley E.V., Drysdale S.B., Le Doare K., Muyembe Tamfum J.J. Paediatric, maternal, and congenital mpox: a systematic review and meta-analysis. Lancet Glob. Health. 2024; 12(4):e572-e588. DOI: 10.1016/S2214-109X(23)00607-1.

10. Islam M.R., Nowshin D.T., Khan M.R., Shahriar M., Bhuiyan M.A. Monkeypox and sex: sexual orientations and encounters are key factors to consider. Health Sci. Rep. 2023; 6(1):e1069. DOI: 10.1002/hsr2.1069.

11. Cabanillas B., Murdaca G., Guemari A., Torres M.J., Azkur A.K., Aksoy E., Vitte J., Fernández-Santamaria R., Karavelia A., Castagnoli R., Valdelvira R., Orsi A., Ogliastro M., Massaro E., Yücel E.Ö., Novak N., Agache I., Akdis M., Akdis C.A. Monkeypox 2024 outbreak: Fifty essential questions and answers. Allergy. 2024; 79(12):3285–309. DOI: 10.1111/all.16374.

12. Pinto P., Costa M.A., Gonçalves M.F.M., Rodrigues A.G., Lisboa C. Mpox person-to-person transmission – where have we got so far? A systematic review. Viruses. 2023; 15(5):1074. DOI: 10.3390/v15051074.

13. Mobilisation des ressources contre le mpox : le Congo lance un appel à la solidarité internationale. (Cited 28 Feb 2025). [Internet]. URL: https://sante.gouv.cg/mobilisation-des-ressources-contre-le-mpox-le-congo-lance-un-appel-a-la-solidarite-internationale.

14. CDC. Mpox in Animals and Pets. (Cited 28 Feb 2025). [Internet]. Available from: https://www.cdc.gov/mpox/about/mpoxin-animals-and-pets.html?CDC_AAref_Val=https://www.cdc.gov/poxvirus/mpox/veterinarian/mpox-in-animals.html/.

15. [Real-time statistics. Population data of any country]. (Cited 28 Feb 2025). [Internet]. Available from: https://countrymeters.info/ru.

16. UNICEF, for every child. (Cited 28 Feb 2025). [Internet]. Available from: https://www.unicef.org/.

17. Rivers C., Watson C., Phelan A.L. The resurgence of mpox in Africa. JAMA. 2024; 332(13):1045–6. DOI: 10.1001/jama.2024.17829.

18. Featherston J., Grobbelaar A.A., Glass A., Goedhals D., Hoek K., Maritz J., Govender K., Govender N., Ismail A., le Roux Ch., Marshall T., Morobadi D., Moodley M., Moolla N., Mtshali S., Msimang V., Vardas E., Weyer J. Preliminary report on the molecular epidemiology of mpox, South Africa 2024. bioRxiv. 2024 Nov 8: 2024-11. DOI: 10.1101/2024.11.07.622575.

19. Vardas E., Naidoo M., Chopdat N.A., Weyer J., Ranchod A.I., Moosa L., Glass A.J., Blumberg L.H., Elskie J., Garyson W., Pitjadi T.M. Severe mpox in an immunocompromised patient, South Africa 2024. South African Medical Journal. 2024; 114(10):33–7. DOI: 10.7196/SAMJ.2024.v114i10.2407.

20. Leendertz S.A.J., Stern D., Theophil D., Anoh E., Mossoun A., Schubert G., Wiersma L., Akoua-Koffi C., Couacy-Hymann E., Muyembe-Tamfum J.J., Karhemere S., Pauly M., Schrick L., Leendertz F.H., Nitsche A. A cross-sectional serosurvey of anti-or-thopoxvirus antibodies in Central and Western Africa. Viruses. 2017; 9(10):278. DOI: 10.3390/v9100278.

21. [Parliamentary newspaper. Lvova-Belova spoke about the situation that children are in in Africa]. (Cited 28 Feb 2025). [Internet]. Available from: https://www.pnp.ru/politics/lvova-belovarasskazala-o-polozhenii-detey-v-afrike.html.

22. Iroezindu M.O., Crowell T.A., Ogoina D., Yinka-Ogunleye A. Human mpox in people living with HIV: epidemiologic and clinical perspectives from Nigeria. AIDS Res. Hum. Retroviruses. 2023; 39(11):593–600. DOI: 10.1089/AID.2023.0034.

23. Saldana C.S., Kelley C.F., Aldred B.M., Cantos V.D. Mpox and HIV: a narrative review. Curr. HIV/AIDS Rep. 2023; 20(4):261–9. DOI: 10.1007/s11904-023-00661-1.

24. Mitjà O., Alemany A., Marks M., Lezama Mora J.I., Rodríguez-Aldama J.C., Torres Silva M.S., Corral Herrera E.A., Crabtree-Ramirez B., Blanco J.L., Girometti N., Mazzotta V., Hazra A., Silva M., Montenegro-Idrogo J.J., Gebo K., Ghosn J., Peña Vázquez M.F., Matos Prado E., Unigwe U., Villar-García J., WaldDickler N., Zucker J., Paredes R., Calmy A., Waters L., Galvan-Casas C., Walmsley S., Orkin C.M.; SHARE-NET writing group. Mpox in people with advanced HIV infection: a global case series. Lancet. 2023; 401(10380):939–49. DOI: 10.1016/S0140-6736(23)00273-8.